Table 1.

Mammary gland developmental scores.

	Female offspring age in postnatal days
	PND 1	PND 3	PND 5	PND 10	PND 22	PND 29	PND 32	PND 42	PND 63
Restricted-exposure study dose groups
Control	–	–	–	–	–	3.6 ± 0.1	3.6 ± 0.1	–	–
GD 7–17	–	–	–	–	–	2.1 ± 0.1*	1.9 ± 0.1*	–	–
GD 10–17	–	–	–	–	–	2.0 ± 0.2*	2.2 ± 0.2*	–	–
GD 13–17	–	–	–	–	–	2.2 ± 0.1*	2.5 ± 0.1*	–	–
GD 15–17	–	–	–	–	–	2.0 ± 0.2*	2.3 ± 0.3*	–	–
Early cross-foster study dose groups
Control	3.3 ± 0.2	3.5 ± 0.2	3.0 ± 0.1	2.8 ± 0.2	–	–	–	–	–
5L	1.7 ± 0.4*	1.8 ± 0.2*	1.5 ± 0.1*	2.3 ± 0.2*	–	–	–	–	–
5U	1.9 ± 0.2*	1.9 ± 0.3*	2.0 ± 0.2*	1.4 ± 0.1*	–	–	–	–	–
5U + L	1.5 ± 0.2*	1.7 ± 0.3*	1.1 ± 0.1*	1.5 ± 0.2*	–	–	–	–	–
Late cross-foster study dose groups
Control	–	–	–	–	3.7 ± 0.1	–	–	3.2 ± 0.2	3.1 ± 0.2
3L	–	–	–	–	3.0 ± 0.2	–	–	2.5 ± 0.2*	2.6 ± 0.2*
5L	–	–	–	–	2.1 ± 0.2*	–	–	2.5 ± 0.1*	2.4 ± 0.2*
3U	–	–	–	–	1.8 ± 0.2*	–	–	2.2 ± 0.1*	2.6 ± 0.2*
5U	–	–	–	–	2.1 ± 0.3*	–	–	2.2 ± 0.2*	1.9 ± 0.2*
3U + L	–	–	–	–	1.8 ± 0.2*	–	–	2.7 ± 0.2	2.6 ± 0.3*
5U + L	–	–	–	–	1.2 ± 0.2*	–	–	1.9 ± 0.2*	1.9 ± 0.2*

Note. Data are presented as mean ± S.E. Scores are on a 1–4 scale; criteria adjusted for stage of development and age. Due to the outbred nature of the CD-1 mouse strain, the mean score for controls was less than 4. Dashes (–) signify time points where no measure was taken within the given study. N = 10–21 adult females per treatment group per time point for the restricted-exposure study. N = 4 litters (3 pups per litter) per treatment group per time point for the early-life effects cross-foster study. N = 9–18 adult females per treatment group per time point for the late-life effects cross-foster study. Statistical comparisons made are with controls within a given study; inter-group comparisons can be found in Section 3.

^*Significant treatment effect compared to control; p < 0.05.